{"title":"长春新碱:治疗卡萨巴赫-梅里特综合征的新选择","authors":"S. Avasthi","doi":"10.4314/IJMU.V6I2.68195","DOIUrl":null,"url":null,"abstract":"Kasabach-Merritt syndrome (KMS) is characterized by a rapidly enlarging hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption coagulopathy as a result of platelet and red blood cell trapping and activation of clotting system within the vasculature of hemangioma. This syndrome is shown to be associated with kaposiform hemangioendotheliomas or tufted hemangioma.","PeriodicalId":14472,"journal":{"name":"Internet Journal of Medical Update - EJOURNAL","volume":"89 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vincristine: A new treatment option for Kasabach-Merritt Syndrome\",\"authors\":\"S. Avasthi\",\"doi\":\"10.4314/IJMU.V6I2.68195\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Kasabach-Merritt syndrome (KMS) is characterized by a rapidly enlarging hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption coagulopathy as a result of platelet and red blood cell trapping and activation of clotting system within the vasculature of hemangioma. This syndrome is shown to be associated with kaposiform hemangioendotheliomas or tufted hemangioma.\",\"PeriodicalId\":14472,\"journal\":{\"name\":\"Internet Journal of Medical Update - EJOURNAL\",\"volume\":\"89 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Internet Journal of Medical Update - EJOURNAL\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4314/IJMU.V6I2.68195\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internet Journal of Medical Update - EJOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/IJMU.V6I2.68195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Vincristine: A new treatment option for Kasabach-Merritt Syndrome
Kasabach-Merritt syndrome (KMS) is characterized by a rapidly enlarging hemangioma, thrombocytopenia, microangiopathic hemolytic anemia and consumption coagulopathy as a result of platelet and red blood cell trapping and activation of clotting system within the vasculature of hemangioma. This syndrome is shown to be associated with kaposiform hemangioendotheliomas or tufted hemangioma.